{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T11:07:29Z","timestamp":1769598449901,"version":"3.49.0"},"reference-count":14,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2017,12,12]],"date-time":"2017-12-12T00:00:00Z","timestamp":1513036800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Given that there are currently no clear recommendations regarding therapeutic options for rituximab refractory\/relapsed follicular lymphoma patients, this study aimed to describe the real\u2010life management of patients with refractory follicular lymphoma after systemic rituximab\u2010containing regimens (<jats:styled-content style=\"fixed-case\">rFL<\/jats:styled-content>), and <jats:styled-content style=\"fixed-case\">rFL<\/jats:styled-content> patient characteristics. In this retrospective, national, multicentre study, descriptive analyses were mainly performed according to rituximab\u2010containing regimen at <jats:styled-content style=\"fixed-case\">rFL<\/jats:styled-content> diagnosis [rituximab monotherapy (R\u2010<jats:styled-content style=\"fixed-case\">MONO<\/jats:styled-content>), rituximab\u00a0+\u00a0chemotherapy (R\u2010<jats:styled-content style=\"fixed-case\">COMBO<\/jats:styled-content>), and ongoing rituximab maintenance (R\u2010<jats:styled-content style=\"fixed-case\">MAINTAIN<\/jats:styled-content>)]. The 459 analysed patients experienced rituximab\u2010refractoriness between October 2013 and September 2015: R\u2010<jats:styled-content style=\"fixed-case\">MONO<\/jats:styled-content>: 58 (13%), R\u2010<jats:styled-content style=\"fixed-case\">COMBO<\/jats:styled-content>: 197 (43%), R\u2010<jats:styled-content style=\"fixed-case\">MAINTAIN<\/jats:styled-content>: 204 (44%). Post\u2010refractoriness strategies were heterogeneous: idelalisib\u00a0\u00b1\u00a0rituximab (22%), without anti\u2010lymphoma treatment (21%), rituximab\u2010chemotherapy (21%) and stem cell transplantation (18%). Rituximab was continued in combination in 41% of cases. Chosen strategies varied according to patient age (without anti\u2010lymphoma treatment: 28% of patients if \u226565\u00a0years vs. 12% if &lt;65\u00a0years old; stem\u2010cell transplantation: 4% vs. 38%), treatment line at <jats:styled-content style=\"fixed-case\">rFL<\/jats:styled-content>,<jats:styled-content style=\"fixed-case\"> FL<\/jats:styled-content> International Prognostic Index score and prior treatment. This French retrospective study, the first one conducted in a large cohort of <jats:styled-content style=\"fixed-case\">rFL<\/jats:styled-content> patients, showed that further strategies were highly heterogeneous, depending notably on patient characteristics and previous treatment. These data are the basis for a better understanding of <jats:styled-content style=\"fixed-case\">rFL<\/jats:styled-content> management and for the design of clinical trials in these patients.<\/jats:p>","DOI":"10.1111\/bjh.15023","type":"journal-article","created":{"date-parts":[[2017,12,12]],"date-time":"2017-12-12T08:04:55Z","timestamp":1513065895000},"page":"217-223","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A retrospective study on the management of patients with rituximab refractory follicular lymphoma"],"prefix":"10.1111","volume":"180","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3953-972X","authenticated-orcid":false,"given":"Philippe","family":"Solal\u2010C\u00e9ligny","sequence":"first","affiliation":[{"name":"Institut de Canc\u00e9rologie de l'Ouest Saint Herblain France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Leconte","sequence":"additional","affiliation":[{"name":"Medical Affairs, Roche France Boulogne\u2010Billancourt France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aur\u00e9lie","family":"Bardet","sequence":"additional","affiliation":[{"name":"Medical Affairs, Roche France Boulogne\u2010Billancourt France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juana","family":"Hernandez","sequence":"additional","affiliation":[{"name":"Medical Affairs, Roche France Boulogne\u2010Billancourt France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Troussard","sequence":"additional","affiliation":[{"name":"University hospital Caen France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,12,12]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-02-702761"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.03014.x"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu200"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.4618"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0016"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2015.0075"},{"key":"e_1_2_8_8_1","volume-title":"Applied Logistic Regression","author":"Hosmer D.W.","year":"1989"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-3175"},{"key":"e_1_2_8_10_1","unstructured":"Monnereau A. Remontet L. Maynadi\u00e9 M. Binder\u2010Foucard F. Belot A. Troussard X.&Brossard N.(2013a)Estimation nationale de l'incidence des cancers en France entre 1980 et 2012. Partie 2 \u2013 H\u00e9mopathies malignes.Institut de veille sanitaire Saint\u2010Maurice."},{"key":"e_1_2_8_11_1","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1002\/ijc.27889","article-title":"Unbiased estimates of long\u2010term net survival of hematological malignancy patients detailed by major subtypes in France","volume":"32","author":"Monnereau A.","year":"2013","journal-title":"International Journal of Cancer"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00155-6"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.8327"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-153189"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62175-7"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.15023","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.15023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T07:29:41Z","timestamp":1695972581000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.15023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,12]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["10.1111\/bjh.15023"],"URL":"https:\/\/doi.org\/10.1111\/bjh.15023","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,12]]},"assertion":[{"value":"2017-06-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-09-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-12-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}